info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Meningococcal Vaccines Companies

Several pharmaceutical companies are involved in the development and production of meningococcal vaccines, which are crucial for preventing meningococcal disease, a severe bacterial infection that can lead to meningitis and septicemia.

Meningococcal Vaccines Key Companies.jpgDisclaimer: List of key companies in no particular orderLatest meningococcal vaccines Companies Update



  • October 2023: The US Food and Drug Administration (FDA) has authorized Pfizer's Penbraya as the first pentavalent vaccination that protects people between the ages of ten and twenty-five against the five most frequent serogroups that cause meningococcal illness. Meningococcal disease is a rare but dangerous infection that can cause death in as little as 24 hours and leave survivors with severe, lifelong disability. As of right now, Pfizer is authorized to market two vaccines to ward against meningococcal group B, known as Trumenba, and groups A, C, W, and Y, known as Nimenrix. By lowering the total number of doses required to be adequately protected against the five serogroups, Penbraya streamlines the meningococcal vaccination schedule and may result in a higher immunization rate among adolescents and young adults. Penbraya mixes the components from both vaccines.




  • March 2023: GSK announced encouraging trial findings for its eagerly awaited combination meningitis vaccine, almost three years after dosing the first patient in a phase 3 study. The shot targets meningitis and blood poisoning caused by the A, B, C, W, and Y families of meningococcal bacteria. It combines the two authorized vaccines from GSK, Menveo and Bexsero. Nearly all occurrences of invasive meningococcal disease (IMD) worldwide are caused by serogroups A, B, C, W, and Y, according to a statement from GSK. In order to be protected against all five groups, one must currently receive four shots from two different vaccinations in the United States. GSK said that the experiment, which included healthy participants aged 10 to 25, achieved its goals with the vaccine candidate. The vaccination produced a “clinically meaningful immune response,” matching up to Bexsero and Menveo.


List of meningococcal vaccines Key companies in the market

  • Pfizer Inc (US)

  • Novartis AG (Switzerland)

  • Sanofi S.A.(France)

  • Serum Institute of India Pvt. Ltd (India)

  • GlaxoSmithKline plc (UK)

  • Merck & Co., Inc (US)

  • Incepta Pharmaceuticals Ltd (Bangladesh)

  • BIO-MED (US)

  • Walvax Biotechnology Co., Ltd (China)

  • Bio-Manguinhos (Brazil)

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.